Business Context and Reporting Period
Company: MoonLake Immunotherapeutics (MLTX)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: MoonLake is a clinical-stage biotechnology company focused on developing Sonelokimab (SLK), a novel tri-specific IL-17A and IL-17F inhibiting Nanobody. The company targets inflammatory skin and joint diseases, specifically hidradenitis suppurativa (HS), psoriatic arthritis (PsA), axial spondyloarthritis (axSpA), and palmoplantar pustulosis (PPP). The company has no approved products and has not generated product revenue.
Key Financial Metrics
| Metric (in millions) | 2025 | 2024 |
|---|---|---|
| Revenue | $0.0 | $0.0 |
| Net Loss | $(230.3) | $(121.2) |
| Operating Expenses | $(244.8) | $(143.1) |
| Research & Development (R&D) | $(202.9) | $(112.8) |
| General & Administrative (G&A) | $(42.0) | $(30.3) |
| Interest Expense | $(7.2) | $0.0 |
| Cash & Cash Equivalents (Year End) | $334.5 | $180.4 |
| Total Liquidity (Cash + Short-term Investments) | $394.0 | $448.0 |
| Long-Term Debt (Carrying Value) | $74.1 | $0.0 |
Note: The company reported a net loss of $230.3 million for 2025, driven by increased clinical trial costs and the initiation of a term loan facility.
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss increased by 90.0% year-over-year, primarily due to a 79.9% increase in R&D expenses ($90.1 million increase) and a 38.4% increase in G&A expenses ($11.7 million increase).
- R&D Drivers: The rise in R&D costs was attributed to the Phase 3 VELA program in HS, the Phase 3 IZAR program in PsA, and additional trials in adolescent HS, PPP, and axSpA. Manufacturing costs also rose significantly due to stockpiling pre-launch inventory.
- Debt Financing: In March 2025, the company entered a $500 million Loan and Security Agreement with Hercules Capital. An initial tranche of $75 million was funded, resulting in $7.2 million of interest expense in 2025 (compared to none in 2024).
- Equity Financing: In November 2025, the company completed a public offering of 7.14 million shares, raising net proceeds of $72.4 million.
- Cash Flow: Net cash used in operating activities increased to $196.0 million in 2025 from $116.6 million in 2024. However, net cash provided by financing activities increased to $146.0 million, supported by debt and equity proceeds.
Guidance, Outlook, and Risks
Clinical Progress and Outlook
- HS (Hidradenitis Suppurativa): Phase 3 VELA-1 met its primary endpoint. VELA-2 did not meet the primary endpoint using the composite strategy due to a higher-than-expected placebo response, though it met the treatment policy strategy. The FDA confirmed in January 2026 that the company may establish substantial evidence of effectiveness without additional trials. A Biologics License Application (BLA) is expected in the second half of 2026, with a potential commercial launch in the second half of 2027.
- PsA (Psoriatic Arthritis): Phase 3 IZAR-1 enrollment completed in February 2026. Readouts for IZAR-1 and IZAR-2 are expected in mid-2026 and the second half of 2026, respectively.
- PPP (Palmoplantar Pustulosis): Received FDA Fast Track designation in February 2026. Phase 3 trial initiation expected in Q3 2026.
- axSpA (Axial Spondyloarthritis): Positive Phase 2 results announced in February 2026; next steps are being evaluated.
Liquidity and Capital Resources
Management believes existing cash, cash equivalents, and short-term marketable securities ($394.0 million as of Dec 31, 2025) are sufficient to fund operations into the second half of 2027. The company has $250.0 million in remaining undrawn tranches under its credit facility, though some milestones were not met in 2025. A subsequent amendment in February 2026 revised tranches and covenants, allowing for an additional $25.0 million draw.
Risks and Contingencies
- Clinical Trial Outcomes: The company is substantially dependent on the success of SLK. Failure of ongoing Phase 3 trials (IZAR program) or safety issues could prevent regulatory approval.
- Debt Covenants: The Loan and Security Agreement contains financial covenants and events of default. Failure to meet milestones or covenants could trigger immediate repayment obligations.
- Legal Proceedings: A putative class action lawsuit (Peters v. MoonLake Immunotherapeutics) was filed in October 2025 alleging false statements regarding clinical benefits. The company intends to vigorously defend the claims.
- Regulatory Uncertainty: Approval timelines and requirements are subject to change by the FDA and EMA. The company faces risks related to government shutdowns and policy changes affecting regulatory review speeds.
Key Facts for Investor Verification
- BLA Submission Timeline: Verify the company's ability to submit the HS BLA in the second half of 2026 as planned, given the mixed results in the VELA-2 trial.
- Debt Facility Status: Confirm the terms of the February 2026 amendment to the Loan and Security Agreement and the company's compliance with revised financial covenants.
- Cash Burn Rate: Monitor the quarterly cash burn rate to ensure the runway extends to the second half of 2027 without requiring immediate dilutive equity raises.
- Legal Proceedings: Track the status of the Peters class action lawsuit and any potential settlement costs or reputational impact.
- Phase 3 Readouts: Watch for the mid-2026 and late-2026 readouts of the IZAR-1 and IZAR-2 trials in PsA, which are critical for the company's diversification beyond HS.